ew In-Une J , 21 2: I - Gilead Sciences Inc. HCV Still Near and LT Focus Upside Sovaldi (4611M vs cons) drove a $0.57 EPS beat: Sovaldi (4611M), Truvada (+$18M), Viread (+$24M) and Complera (+$22M) drove the $685M rev beat vs cons. Better gross margins (89% vs MSe 86%) and a lower tax rate (14.6% w

-out of two advancements in the fight against HIV/AIDS have received: the HIV prevention pill, and the at-home HIV test. Marketed under the name of Truvada (also known as PrEP, which employs a combination of medications already being used to treat AIDS), the HIV prevention pill does not eliminate, but d